![]() ![]() Clinical Benefit Rate remained unchanged at 85.7%. N3 designation 1.īased on these criteria, results showed that lacutamab produced an increased global objective response rate (ORR) of 42.9% (95% confidence interval, 24.5-63.5) in patients with KIR3DL2 ≥ 1% MF (cohort 2, n=21), including 2 complete responses and 7 partial responses. ![]() In a recent update to the Olsen 2011 guidelines, it was clarified that the pathological assessment of lymph nodes be limited to those that satisfy nodal lymphoma i.e. Lymph Node assessment is an important component of staging and response assessment in CTCL (cutaneous T cell lymphomas). In the KIR3DL2 non-expressing cohort (cohort 3, n=18), patients received a median of 4.5 prior systemic therapies and had a median follow-up of 13.8 months. The data were previously presented at the 17th International Conference on Malignant Lymphoma, in Lugano (Switzerland), in June 2023.Īs of March 4, 2022, data cutoff, patients in the KIR3DL2-expressing MF cohort (cohort 2, n=21) received a median of 4 prior systemic therapies, and had a median follow-up of 12.2 months. The data confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. MARSEILLE, France-( BUSINESS WIRE)-Innate Pharma SA (Euronext Paris: IPH Nasdaq: IPHA) (“ Innate” or the “ Company”) today announced an encore presentation of interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated guidelines (Olsen 2022 1) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023, being held September 21-23, 2023 in Leiden, the Netherlands. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |